To print this article, all you need is to be registered or login on Mondaq.com.
According to the notification, the Central Government proposes
to provide benefits to the eligible educational institutions for
promoting patent filing by such institutes and has accordingly
proposed changes to the Rules 2, 7, 24C and Fee Schedule of the
Indian Patent Rules, 2003 and the Central Government has now
invited objections and suggestions from the public and
stakeholders, to be submitted within a period of 30 days from the
date on which the notification was published in the Official
Gazette i.e. by March 11, 2021.
Amendments Proposed to Patent Rules, 2003
(1)
Cobalt Iron Inc. today announced that the company has been granted a U.S. patent entitled Data Protection Automatic Optimization System and Method. Issued on Jan. 12, 2021, U.S. Patent #10891200 describes new capabilities for the Cobalt Iron Compass enterprise software-as-a-service (SaaS) backup platform that enable automatic and dynamic adjustment to data collection activities in response to a detected event or condition.
The patent addresses a large, unmet requirement for data collection and effective monitoring in the enterprise backup world. Deeper data collection and monitoring can be necessary to help identify, remediate, and track issues. However, adequate data collection of these metrics is seldom performed. Even when some data is collected, it typically is static in nature.
This decision concerns the way how applications can be installed on a mobile phone's SIM, One might not expect big surprises concerning the technical character in this field, but the board.
Hancock Jaffe Laboratories, Inc.: First U.S. Patent Allowed on Hancock Jaffe VenoValve
IRVINE, CA / ACCESSWIRE / February 24, 2021 /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the company s VenoValve. The patent, which focuses on novel aspects of the VenoValve frame, will be the first to issue among several VenoValve patent applications pending in the U.S. and throughout the world.
The VenoValve is a clinical stage device that is being developed to treat a debilitating condition known as chronic venous insufficiency (CVI) of the deep venous system. CVI occurs when valves inside the veins of the leg fail, causing blood to flow in the wrong direction (reflux), and increasing venous pressure (venous hypertension). This results in leg swelling, pain, open sores (venou
(1)
LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) OKYO Pharma Limited ( OKYO or the Company ), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, today announced that patent No. 10,899,796 entitled Compounds and Methods for Treating Pain was issued by the United States Patent and Trademark Office ( USPTO ) on January 26, 2021. This patent covers a class of bovine adrenal medulla (BAM) peptides linked to specific lipids that demonstrate potential for treating symptoms of neuropathic pain, ocular pain, ocular inflammation and/or dry eye disease.
The work recited in this patent lays out the potential of this class of lipidated BAM analogues as non-opioid analgesics for ocular pain management without the side effects and potential abuse associated with opioid medications. The Company originally announced in February 2018 that it had obtained exclusive licenses from On Target Therapeutics LLC and Tufts Medical C